Called $GOOGL bullish on Apr 29, 2025: $GOOGL rose 112% in 9 months.
View call →GARP Investing: Great Businesses + Attractive Valuations. Deep fundamental analysis paired with tactical entry zones
Cite asCryptoQuant has tracked the directional calls on NVO by @qualitystocks on Substack since Dec 2023: not yet scored on NVO (as of Nov 19, 2026).
Other assets covered (16)
4 NVO calls on record, a thin history.
Relative view by default: fewer than 30 NVO calls or days on record.
Sentiment timeline shows relative sentiment within this analyst's history. A perma-bull showing 8 bullish : 2 bearish in a bear market sets that as their baseline. If you notice any errors, claim @substack:qualitystocks to submit corrections.
Hover the chart to read the thesis of that period · click a day to pin it
The Weekly Screener - November, 09: Halozyme, Novo Nordisk, Booking, Mercadolibre & Datadog
Welcome to “The Weekly Screener” . Every week, I merge fundamentals and technicals through the Quality Stocks Investment Framework to evaluate actionable setups, fair values and key buy execution zones (along with my personal verdict on every stock). 💡 Verdict thresholds: When relevant, I also indicate the price at which valuation alone would trigger an upgrade in my verdict, assuming the fundamental outlook remains unchanged. 🎯 Paid subscribers unlock the complete breakdown for all the stocks and can nominate tickers to be featured in next week’s edition Join 22,000+ investors receiving our weekly GARP research 📚 Browse the “Weekly Screener” archive Edition of November 02, 26. Fortinet, Visa, Evolution, Nemetschek, GE Vernova Edition of October 25, 26. MSCI, RTX, SpaceX, Rollins, Netflix Edition of October 17, 26 . Blackrock, Generac, DLocal, Boston Scientific, Elastic Edition of October 11, 26 . Vistra, Halozyme, Avnet, McCormick, Pepsico Edition of October 04, 26 . Accenture, Adyen, Equasens, Nike, Applovin Edition of September 27, 26. Rollins, Eton, Insmed, Roblox, FlatexDegiro Edition of September 20, 26. McDonald’s, Evolution, Alcon, QXO, Xylem Edition of September 13, 26 . Adobe, Celestica, Modine, Sea Ltd, Intuit Edition of September 06, 26 . Lululemon, Fair Isaac, Theon, Applovin, Palo Alto Networks Edition of August 30, 26 . Veeva, Vistra, Crowdstrike, Okta, Alibaba Edition of August 23, 26 . Walmart, Taiwan Semiconductor, Reddit, Moderna, Oracle Edition of August 16, 26 . Netflix, On Holding, The Trade Desk, Adyen & Shift4 Payments 📅 The companies featured this week The stocks for this week are: Halozyme (HALO), Novo Nordisk (NVO), Booking (BKNG), Mercadolibre (MELI) & Datadog (DDOG) Data for my analyses are sourced via MarketScreener . It is my go-to platform for global stock data . If you are looking to upgrade your research toolkit, click here (Full disclosure: this is an affiliate link, so you will be supporting this newsletter at no extra cost to you!) The Quality Stocks Investment Framework Here is a quick refresher on how the Quality Stocks Investment Framework translates fundamentals into disciplined execution because we want to find great businesses built for the decade, bought at execution targets built for right now. 🔎 FIND → 🏢 UNDERSTAND → 💰 VALUE → 🎯 EXECUTE → 🚪 EXIT To dive deeper into the complete process, read the full Investment Framework guide Stock 1: Halozyme ($HALO) 💎 Fundamental Overview 🟢 Growth 90/100 🟢 Quality 87/100 🟡 Valuation 65/100 Current price: $103 Potential TSR: 13.4% per year Fair value: $97 (base) / $81 (bear) / $134 (bull) Halozyme delivered another strong quarter in Q3 2026, with revenue growing 39% YoY to $493M, royalty revenue increasing 44% to $341M. Management also raised its full-year guidance. Despite these impressive results, investors remain focused on loss-of-exclusivity risks, a recurring concern across the pharmaceutical sector. In Halozyme’s case, the expiration of key ENHANZE patents could put pressure on future royalty streams. For example, European royalty rates on DARZALEX SC, one of the company’s largest revenue contributors, could decline following the expiration of a key patent in March 2029. To mitigate this risk, management is pursuing a strategy centered on diversifying and extending its royalty portfolio, expanding partnerships with major pharmaceutical companies, accelerating new product launches and investing in next-generation drug-delivery technologies such as Hypercon and Aerocon 🎯 Buy Zones Buy zone 1 : $80 - 🟢 Moderately attractive below $80 Buy zone 2 : $60 - 🟢 Highly attractive below $60 Buy zone 3 : $47 💡 My Take on Halozyme: 🟡 Conditional Halozyme has been one of the success stories of my Multibagger Hunting portfolio. I first initiated a position in 2024 at around $45 per share, and before the recent pullback, the stock had become a 3-bagger. However, following its strong share price appreciation, I downgraded my assessment from Moderately Attractive to Conditional in my latest portfolio update , reflecting a less compelling risk-reward profile at elevated valuations. The recent correction is therefore not entirely surprising, particularly after such a strong rally. At this stage, patience is key. I prefer to let the stock consolidate and wait for more attractive entry points before considering adding to my position Join 22,000+ investors receiving our weekly GARP research Read more
View original →